Survivin

Survivin

The IAP family of inhibitors of apoptosis (IAP) includes survivin. As a result of the survivin protein's ability to prevent caspase activation, apoptosis, or programmed cell death, is negatively regulated. This has been demonstrated by disruption of the pathways that induce survivin, which increases apoptosis and slows tumor growth. Only the G2-M phase of the cell cycle results in the expression of the survival protein. By interacting with tubulin during mitosis, survival localizes to the mitotic spindle and may help control the process. Antisurvivin therapy is a promising cancer treatment option because survivin is highly expressed in the majority of cancers and linked to chemotherapy resistance, increased tumor recurrence, and decreased patient survival.

Survivin related products

Structure Cat No. Product Name CAS No. Product Description
V4436 GDP366 501698-03-9 GDP366 is a novel, potent, selective small molecule and dual inhibitor of survivin and Op18, it induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.
V2178 LQZ 7I 195822-23-2 LQZ-7I is a novel malarial protease PfSUB1 inhibitor.
V0771 YM155 (Sepantronium Bromide) 781661-94-7 YM155 (also called Sepantronium Bromide; YM-155; YM 155) is a novel and potent survivin inhibitor with potential anticancer activity.
Contact Us